Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc. (WGRX) filed a Form 8-K to announce that it issued a press release reporting its financial results for the quarter ended September 30, 2025. The press release, dated November 20, 2025, is furnished as Exhibit 99.1 to the report.
The company notes that the press release includes forward-looking statements about its projects, potential financial performance, and growth opportunities, which are subject to risks and uncertainties described in its SEC filings, including its Form S-1 declared effective on September 25, 2025. The information in Items 2.02 and 7.01 is being furnished, not filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other SEC filings.
Wellgistics Health, Inc. (WGRX)$21.7 million for the nine months, primarily from product distribution, pharmacy retail sales, and third-party logistics, but were outweighed by operating expenses of $69.8 million, including $54.4 million of stock-based compensation. The company posted a nine‑month net loss of $73.4 million versus $2.5 million a year earlier and ended the period with $4.2 million in cash and total debt of $24.8 million.
Management concluded that these losses, negative operating cash flow, and high leverage raise substantial doubt about the company’s ability to continue as a going concern without additional capital. To bolster liquidity, Wellgistics completed a February 2025 IPO raising about $3.1 million net, used an equity purchase agreement to raise $2.8 million, and in September 2025 sold 7,142,862 shares with matching warrants for net proceeds of $4.5 million, followed by warrant exercises that brought in another $2.2 million.
Wellgistics Health, Inc. reported that its independent auditor, UHY LLP, resigned as the company’s independent accountants effective November 11, 2025. UHY stated it elected to resign in light of certain information identified in the resignation of the former Chief Executive Officer, which had not yet been investigated, and it did not audit any of the company’s financial statements before resigning.
The company states there were no disagreements with UHY on accounting principles, financial statement disclosure, or audit procedures, and no additional reportable events beyond previously disclosed material weaknesses in internal control over financial reporting. These weaknesses include an underdeveloped control environment, limited documentation of policies and procedures, lack of evidence of control performance, and limited accounting personnel. The Audit Committee has approved re-engaging Suri & Co. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Wellgistics Health, Inc. (WGRX) announced board changes approved by written consent. Holders representing 49,825,505 shares of common stock, or approximately 55.5% of total voting power, removed directors Rebecca Shanahan and Michael Peterson without cause; the actions became effective on October 1, 2025 under Delaware law.
Following the removals, the company disclosed that Donald Anderson resigned effective October 2, 2025. On October 2, 2025, the Board elected Donald Fell, Prashant Patel, Steven D. Lee, and Howard Doss as directors. Mr. Patel was appointed President. Mr. Fell, Mr. Lee, and Mr. Doss are described as independent under applicable NASDAQ and SEC rules, and were assigned to key committees, including Audit (chaired by Mr. Doss), Nominating, Compensation, and Ethics.
Shares outstanding were 89,621,242 as of the October 1, 2025 record date. No meeting or proxies were solicited; the information statement serves as notice pursuant to Regulation 14C and DGCL Section 228(e).
Wellgistics Health (WGRX) reported capital-structure changes. Holders exercised warrants at an exercise price of $0.70 per share, resulting in the issuance of 3,111,429 shares of common stock.
The company also entered two debt conversion agreements on October 30, 2025. It converted $1,300,000 of indebtedness into 1,857,143 shares at $0.70 per share, and converted $4,019,859 of indebtedness into 5,742,656 shares at $0.70 per share, in each case in full satisfaction of the underlying obligations.
Wellgistics Health, Inc. (WGRX) furnished a press release as Exhibit 99.1 under Item 7.01 (Regulation FD). The company notes the information is furnished and not deemed filed for Section 18 purposes or incorporated by reference. The release includes forward-looking statements and cautions that actual results may differ due to risks described in SEC filings, including the company’s Registration Statement on Form S-1 declared effective on September 25, 2025.
Wellgistics Health (WGRX) disclosed a Form 3 from director Howard Doss, an initial statement of beneficial ownership. The filing indicates no securities are beneficially owned by the reporting person as of the event date 10/02/2025.
The form was filed by one reporting person and includes a Power of Attorney (Exhibit 24.1). This is a routine ownership disclosure and does not reflect a transaction.
Wellgistics Health (WGRX) announced a non-binding letter of intent with DataVault to explore integrating PharmaChain, a manufacturer-to-patient blockchain-enabled smart contract solution, into Wellgistics’ technology and physical infrastructure for the prescription drug industry.
The contemplated collaboration would focus on digitizing prescription fulfillment workflows with a potential revenue-sharing arrangement, but economic and other material terms remain under negotiation and there is no assurance any agreement or revenues will result. The companies stated the contemplated solution does not involve tokens or digital assets. A joint press release was furnished as Exhibit 99.1.
Wellgistics Health, Inc. (WGRX) announced governance changes approved by written consent of holders representing approximately 55.5% of voting power. Effective October 1, 2025, the majority holders removed Rebecca Shanahan and Michael Peterson from the Board without cause under Delaware law. The consents delivered represented 49,825,505 shares of common stock.
Following the actions, the company disclosed the resignation of Donald Anderson (effective October 2, 2025) and appointed Donald Fell, Prashant Patel, Steven D. Lee, and Howard Doss to the Board on October 2, 2025. The Board named Mr. Patel President and assigned committee roles, including Mr. Doss as Audit Committee chair. The company reported 89,621,242 shares outstanding as of the October 1, 2025 record date, and identified three new directors as “independent” under applicable NASDAQ and SEC rules.
Wellgistics Health, Inc. (WGRX) reported a new insider status change: Director Donald Fell filed a Form 3 initial statement of beneficial ownership. The filing states that no securities are beneficially owned.
The event date is 10/02/2025, indicating the point at which the reporting obligation began. This is an administrative disclosure under Section 16 and does not reflect a transaction or change in the company’s capital.